STOCK TITAN
  1. Home
  2. News
  3. ACRS

Aclaris Therapeutics Inc - ACRS STOCK NEWS

Welcome to our dedicated news page for Aclaris Therapeutics (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aclaris Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aclaris Therapeutics's position in the market.

News
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Rhea-AI Summary
Flare Therapeutics appoints Douglas Manion, a seasoned pharmaceutical executive, as the new Chief Executive Officer. Dr. Manion's extensive experience in drug development and leadership roles in biotechnology and pharmaceutical companies positions him well to drive Flare Therapeutics' growth and advance its clinical-stage pipeline. The company aims to revolutionize the field by targeting transcription factors to discover precision medicines for cancer and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Rhea-AI Summary
Aclaris Therapeutics, Inc. announces financial results for Q4 and full year 2023, highlighting positive research and development updates. The company reported a net loss of $1.5 million in Q4 2023, with total revenue reaching $17.6 million. Aclaris had cash, cash equivalents, and marketable securities of $181.9 million as of December 31, 2023. The company is focused on advancing its drug candidates for immuno-inflammatory diseases and seeking development partners. Despite challenges like increased R&D expenses and intangible asset impairment charges, Aclaris remains optimistic about its future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
earnings
-
News
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
Rhea-AI Summary
Aclaris Therapeutics, Inc. announced leadership changes and a strategic review of its business. Dr. Douglas Manion stepped down as CEO and President, with Dr. Neal Walker appointed as Interim CEO. The company also disclosed a preliminary unaudited cash position of approximately $182 million as of December 31, 2023. Aclaris is seeking a development and commercialization partner for its investigational drugs ATI-1777 and ATI-2138, with positive results from recent trials. The company plans to continue advancing discovery programs through its proprietary drug discovery platform, KINect®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.54%
Tags
management
News
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Rhea-AI Summary
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced top-line results from its Phase 2b study of ATI-1777, an investigational topical 'soft' JAK 1/3 inhibitor, in patients with atopic dermatitis. The trial achieved a statistically significant result in the primary efficacy endpoint at week 4, demonstrating response rates on par with existing market competition and a differentiated safety profile. The trial met the primary efficacy endpoint, showing a significant reduction in the Eczema Area and Severity Index (EASI) score at week 4 for patients treated with ATI-1777 2% BID compared to patients treated with the vehicle. A PK analysis showed minimal levels of exposure to ATI-1777, and it was well tolerated with no serious adverse events commonly associated with JAK inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.48%
Tags
clinical trial
-
News
Aclaris Therapeutics Provides Corporate Update
Rhea-AI Summary
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced the publication of Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed journal JID Innovations. The Phase 2b trial topline data is anticipated in January 2024. Aclaris also announced a reduction in workforce and several other corporate updates related to its drug development pipeline and workforce restructuring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
News
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Rhea-AI Summary
Aclaris Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: ACRS), has entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, granting Sun Pharma exclusive rights to use deuruxolitinib to treat alopecia areata and androgenetic alopecia. The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
News
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
Rhea-AI Summary
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announces disappointing results from a Phase 2b study of zunsemetinib in patients with rheumatoid arthritis. Both 20mg and 50mg doses did not meet primary or secondary efficacy endpoints. Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of the ongoing Phase 2a trial in psoriatic arthritis. The company plans to host a conference call and webcast to review the trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-86.44%
Tags
clinical trial
-
News
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Rhea-AI Summary
Aclaris Therapeutics, Inc. announced its financial results for Q3 2023 and provided a corporate update. The company is approaching the topline data read-outs for its two most advanced clinical programs: zunsemetinib in rheumatoid arthritis and ATI-1777 in atopic dermatitis. Zunsemetinib Phase 2b trial in rheumatoid arthritis completed enrollment and topline data is expected this month. ATI-1777 Phase 2b trial in atopic dermatitis completed enrollment and topline data is anticipated around year-end 2023. Aclaris also highlighted the progress of other drug candidates in development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
earnings
-
News
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
Rhea-AI Summary
Aclaris Therapeutics completes enrollment for Phase 2b trial of ATI-1777 in atopic dermatitis, expects top-line data by year end
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
clinical trial
News
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Aclaris Therapeutics to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
conferences
Stock ACRS logo
Aclaris Therapeutics Inc

Nasdaq:ACRS

ACRS Rankings

#4411 Ranked by Market Cap
#5171 Ranked by Stock Gains
N/A Ranked by Dividends

ACRS Stock Data

86.53M
50.39M
2.78%
95.84%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Wayne

About ACRS

aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.